Ousted scientist fires back at GSK’s high-pressure R&D strategy in China

John Carroll GlaxoSmithKline wasn't the only Big Pharma company to set up R&D operations in China. But a feature in Bloomberg today highlights GSK's unusual decision to ...

Sanofi faces bribery allegations from China whistleblower

Tracy Staton Sanofi has joined GlaxoSmithKline in facing bribery allegations in China. According to a Chinese newspaper, the whistleblower says Sanofi paid 1.7 million yuan in bribes ...

China revokes patent on Gilead’s Viread

Eric Palmer In another swipe at the intellectual property of drugmakers in emerging markets, China's State Intellectual Property Office (SIPO) has yanked the patent for Viread, ...

GlaxoSmithKline CEO’s reform-minded rep under fire in China probe

Tracy Staton As the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have ...

China Revokes Patent On Gilead AIDS Drug Over Pricing

esilverman In the latest row between global drugmakers and governments over affordable medicines, China’s State Intellectual Property Office revoked the patent on Viread, ...

Apexigen lands $20M round as China biotech partners advance antibodies

John Carroll Apexigen, a Burlingame, CA-based company that was spun out of Epitomics three years ago, says that much of the money will be used to work on an in-house cancer immunotherapy ...

Baxter caught up in China bribery scandal

John Carroll Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them. FierceBiotech News

WSJ: Baxter acknowledges it found irregular payments by China joint venture

Carly Helfand Baxter uncovered expense violations in July, 2012 from a joint venture in China, which went undisclosed until the WSJ contacted it with an anonymous tipster's information ...

Tension rises in China as officials fine J&J, visit Sanofi

Tracy Staton Amid Chinese government probes of potential graft, corruption and opportunistic pricing, even drugmakers that say they're confident about their compliance expect fallout ...

China detains 18 more GSK staff as probe continues to grow

Carly Helfand Eighteen more GlaxoSmithKline employees are being detained in China as authorities dig deeper into the bribery investigation. And GSK's former China head Mark ...

GSK China Boss Replaced in Wake of Scandal

mia.burns GlaxoSmithKline has replaced the British head of its Chinese operations, which are at the centre of a pounds 320m cash and sexual bribery scandal. Britain’s ...

GlaxoSmithKline replaces head of business in China amid bribery investigation

Carly Helfand Against the backdrop of an ongoing government bribery probe in China, GlaxoSmithKline is shuffling its senior management there. Herve Gisserot is taking over. FiercePharma ...
Page 4 of 8« First...23456...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS